DGM
Darwin Global Management Portfolio holdings
AUM
$2.38B
This Quarter Return
-4.41%
1 Year Return
+81.43%
3 Year Return
+6,053.69%
5 Year Return
–
10 Year Return
–
AUM
$1.06B
AUM Growth
+$1.06B
(-14%)
Cap. Flow
-$46M
Cap. Flow
% of AUM
-4.36%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
3
Increased
2
Reduced
1
Closed
2
Top Buys
| 1 |
Insmed
INSM
|
$170M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$59.7M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$37.6M |
| 4 |
Nurix Therapeutics
NRIX
|
$3.08M |
| 5 |
Keros Therapeutics
KROS
|
$2.59M |
Top Sells
| 1 |
Vaxcyte
PCVX
|
$251M |
| 2 |
Geron
GERN
|
$44.1M |
| 3 |
Summit Therapeutics
SMMT
|
$23.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$28.8B
| $895M | 84.75% | 12,960,538 +2,463,261 | +23% | +$170M |
|
|
2
Jazz Pharmaceuticals
JAZZ
$7.75B
| $59.7M | 5.65% | +484,515 | New | +$59.7M |
|
|
VRNA
3
Verona Pharma
VRNA
$9.16B
| $37.6M | 3.56% | +810,449 | New | +$37.6M |
|
|
4
Geron
GERN
$893M
| $33.9M | 3.21% | 9,569,835 -12,468,938 | -57% | -$44.1M |
|
|
5
Keros Therapeutics
KROS
$618M
| $26.7M | 2.53% | 1,687,135 +163,403 | +11% | +$2.59M |
|
|
6
Nurix Therapeutics
NRIX
$714M
| $3.08M | 0.29% | +163,681 | New | +$3.08M |
|
|
7
Vaxcyte
PCVX
$4B
| – | – | -2,198,187 | Closed | -$251M |
|
|
8
Summit Therapeutics
SMMT
$17.6B
| – | – | -1,084,880 | Closed | -$23.8M |
|